|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Herein, we report the role and mechanism of activating transcription factor 3 (ATF3), a member of the ATF/cAMP-responsive element-binding protein family of transcription factors in HCC.
|
30376856 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, we identified lectin from Bandeiraea simplicifolia seeds (BS-I) binds to metastasis-associated HCC cell surface glycans by a lectin microarray and inhibits HCC cell migration and invasion through downregulating the matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 (MMP9) and urokinase-type plasminogen activator (uPA) production.
|
28922551 |
2018 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, these results show that u-PA expression may be a potent therapeutic target in the DNE-mediated suppression of HCC invasion/migration.
|
26916922 |
2016 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These results show that u-PA expression may be a potent therapeutic target in the TCE-mediated suppression of HCC metastasis.
|
24886639 |
2014 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The miR-193a has resulted a negative regulator of uPA in both the HCC cell lines tested.
|
24330766 |
2013 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We investigated the mechanisms underlying the modulation of SDF-1 expression through uPA stimulation in human HCC SK-Hep-1 cells.
|
21465475 |
2012 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
There existed significant positive correlations between VM and the expression of OPN, MMP-2 and uPA in HCC tissue samples.
|
21512310 |
2011 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In human hepatocellular carcinoma (HCC), the high expression of urokinase-type plasminogen activator (uPA) is an unfavorable prognostic factor and a therapeutic target.
|
19177205 |
2009 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Evidence has suggested that uPA and c-met overexpression may be coordinated in human hepatocellular carcinoma (HCC).
|
19490101 |
2009 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to examine the effects of vector-based RNA interference (RNAi) of u-PA on the growth of human HCC xenografts in nude mice in order to investigate the role of u-PA in human HCC.
|
17159381 |
2007 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma.
|
15217951 |
2004 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
To determine the role of u-PA in the invasiveness properties of HCC, we successfully down-regulated u-PA by RNA interference (RNAi) technology, in an HCC-derived cell line at high level of u-PA expression.
|
15210852 |
2004 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
In conclusion, u-PA down-regulation by RNAi technology decreases the invasive capability of HCC cells, demonstrating that stable expression of siRNA u-PA could potentially be an experimental approach for HCC gene therapy.
|
15210852 |
2004 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Antisense u-PA strategy might be a potential approach to reduce tumor growth as well as the invasive capacity of the malignant cells in HCC.
|
12536199 |
2003 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, c-met mRNA expression was strictly associated with u-PA mRNA level in HCC samples (P = 0.001).
|
10925356 |
2000 |
|
Liver carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.
|
9096588 |
1997 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Both the PEA3--AP-1 element, the AP-1 site and the COM are required for efficient phorbol ester induction of transcription from the uPA promoter in the HepG2 hepatoma cell line.
|
1330539 |
1992 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
MGD |
|
|
|